Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: Results from the nationwide Swedish register: Reply

Rheumatology (United Kingdom)

Volumn 58, Issue 8, 2019, Pages 1510-1511

  Frisell, Thomas ^a   Askling, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; COMPARATIVE EFFECTIVENESS; HUMAN; LETTER; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS;

EID: 85081577273     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kez120     Document Type: Letter

References (1)

1. Frisell T, Dehlin M, Di Giuseppe D, et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology 2019;58:1367-77.